http://www.fpnotebook.com/
Barrett's EsophagusAka: Barrett's Metaplasia
- See Also
- Gastroesophageal Reflux Disease
- Esophageal Adenocarcinoma
- Pathophysiology
- Columnar metaplasia of distal esophagus
- Response to chronic inflammation
- Gastroesophageal Reflux
- Risk Factors
- Gastroesophageal Reflux
- GERD Symptoms > 3x/week for 20 years: RR = 40
- Racial predisposition
- Caucasian
- Hispanic
- Older age
- Tobacco Abuse (2 fold increase in Esophageal Cancer)
- Male gender
- Obesity
- Endoscopy
- Indications for screening for Barrett's Esophagus
- Significant risk factors above
- Red flag symptoms
- Dysphagia
- Odynaphagia
- Upper Gastrointestinal Bleeding
- Weight loss
- Surveillance and management protocol (controversial)
- Consider screening only once in patients with GERD
- Barrett's Esophagus without dysplasia
- Repeat endoscopy with biopsy in one year
- If no dysplasia x2, then endoscopy every 3-5 years
- Low grade dysplasia
- Repeat endoscopy with biopsy in 6 months
- Then repeat upper endoscopy annually
- High grade dysplasia: Upper endoscopy q3 months
- Consider esophagectomy if able to undergo surgery
- Consider ablation if not able to undergo surgery
- Findings consistent with Barrett's Esophagus
- Z-line is squamocolumnar junction
- Z-Line is normally at gastroesophageal junction
- Barrett's Esophagus
- Z-line shifts up from gastroesophageal junction
- Long-segment Barrett's: >3 cm from junction
- Short-segment Barrett's: <3 cm from junction
- Screening difficulties
- Esophageal Cancer is uncommon, even in Barrett's
- Most Esophageal Cancer patients have no GERD symptoms
- Longterm surveillance is still recommended
- References
- Gopal (2002) Evid Based Oncol 3(4):144
- Hage (2004) Scand J Gastroenterol 39:1175
- Endoscopy factors predicting low risk of adenocarcinoma
- Low grade or no dysplasia on initial endoscopy and
- Barrett's Esophagus length <6 cm
- Weston (2004) Am J Gastroenterol 99:1657
- Complications of Barrett's Esophagus
- Esophageal Adenocarcinoma
- Cancer Incidence on first endoscopy: 0.5% per year
- References
- Kahrilas in Feldman (2002) Sleisenger GI, p. 615-8
- Katzka (2003) Hematol Oncol Clin North Am 17(2):471
- Spechler (2002) N Engl J Med 346:836
Navigation Tree